PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 187 filers reported holding PDL BIOPHARMA INC in Q4 2017. The put-call ratio across all filers is 2.92 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $2,565,000 | +7.3% | 872,700 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $2,390,000 | -30.9% | 872,700 | -14.4% | 0.01% | -42.9% |
| Q3 2017 | $3,457,000 | +37.2% | 1,019,800 | 0.0% | 0.02% | +31.2% |
| Q2 2017 | $2,519,000 | +8.8% | 1,019,800 | 0.0% | 0.02% | +6.7% |
| Q1 2017 | $2,316,000 | -63.2% | 1,019,800 | -65.6% | 0.02% | -69.4% |
| Q4 2016 | $6,288,000 | -37.5% | 2,966,602 | -1.1% | 0.05% | -33.8% |
| Q3 2016 | $10,054,000 | +6.4% | 3,000,706 | -0.2% | 0.07% | +2.8% |
| Q2 2016 | $9,445,000 | -7.1% | 3,007,676 | -1.5% | 0.07% | -12.2% |
| Q1 2016 | $10,169,000 | -6.1% | 3,053,252 | -0.2% | 0.08% | -11.8% |
| Q4 2015 | $10,827,000 | -12.4% | 3,058,846 | +24.4% | 0.09% | -1.1% |
| Q3 2015 | $12,366,000 | -21.3% | 2,458,420 | +0.6% | 0.09% | -21.0% |
| Q2 2015 | $15,715,000 | -14.2% | 2,444,134 | -6.1% | 0.12% | -13.8% |
| Q1 2015 | $18,311,000 | -9.3% | 2,602,731 | -0.6% | 0.14% | -4.8% |
| Q4 2014 | $20,192,000 | +72.9% | 2,619,085 | +67.6% | 0.14% | +74.7% |
| Q3 2014 | $11,677,000 | +26.3% | 1,563,014 | +63.6% | 0.08% | +25.8% |
| Q2 2014 | $9,247,000 | +16.8% | 955,288 | +0.2% | 0.07% | +8.2% |
| Q1 2014 | $7,920,000 | +182.6% | 953,063 | +187.0% | 0.06% | +165.2% |
| Q4 2013 | $2,803,000 | – | 332,058 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Argent Trust Co | 41,405 | $102,270 | 0.01% |
| Diversified Trust Co | 11,029 | $26,469 | 0.00% |
| HANCOCK WHITNEY CORP | 128,396 | $0 | 0.00% |
| RHUMBLINE ADVISERS | 612 | $1,511 | 0.00% |
| Ancora Advisors LLC | 4,948 | $0 | 0.00% |
| Westside Investment Management, Inc. | 500 | $0 | 0.00% |